Contract Win

RNS Number : 7872U

IXICO plc

04 August 2022

 

IXICO plc

("IXICO" or the "Company")

Contract win for a Phase 2 Parkinson's disease trial worth over £0.8m

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a leading European biopharmaceutical company to provide MRI and DAT-SPECT imaging services for a Phase 2 clinical trial in Parkinson's disease ('PD'). 

This is the second study award with this client in the last twelve months. IXICO will provide radiology and quantitative analysis services to support patient selection, safety, and efficacy analysis. The trial is expected to be delivered over a period of four and a half years.

Since its inception in 2004, IXICO has built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders across the entire drug development lifecycle, from phase I through to commercialisation.

Giulio Cerroni, CEO of IXICO, commented: " We are delighted to be awarded this contract to support the development of this promising investigational drug in PD.  Our success in being awarded a second study with this client, demonstrates the momentum we are building in expanding into a broader range of neurodegenerative therapeutic indications.  Our mission is to support our current and prospective clients in their efforts to bring potential treatments to patients suffering from neurological disorders, and this contract is an example of the confidence that increasing numbers of companies are placing in IXICO as their trusted neuroimaging partner for their important CNS studies."

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)		[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

END

 

 

CNTUOVKRUBUWRRR